Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors

Retina

Volumn 35, Issue 1, 2015, Pages 69-74

  Krohne, Tim U ^a   Muether, Philipp S ^b   Stratmann, Nina K ^a   Holz, Frank G ^a   Kirchhof, Bernd ^b   Meyer, Carsten H ^c   Fauser, Sascha ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Pallas Clinic   (Switzerland)

Author keywords

axial length; bevacizumab; duration of action; lens status; ocular volume; pharmacokinetics; ranibizumab; refraction; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AQUEOUS HUMOR; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE REFRACTION; HUMAN; LENS; MAJOR CLINICAL STUDY; MEASUREMENT; PSEUDOPHAKIA; ANATOMY AND HISTOLOGY; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; EYE AXIS LENGTH; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RETINAL DISEASES; RETINAL VEIN OCCLUSION; TIME; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; AXIAL LENGTH, EYE; BIOLOGICAL AVAILABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; LENS, CRYSTALLINE; MACULAR EDEMA; MALE; MIDDLE AGED; REFRACTION, OCULAR; RETINAL DISEASES; RETINAL VEIN OCCLUSION; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84920264952     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000265     Document Type: Article

References (24)

1. Muether PS, Hermann MM, Droge K, et al. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol 2013;156:989-993.e982.
2. Teichmann KD. Intravitreal injections: does globe size matter? J Cataract Refract Surg 2002;28:1886-1889.
3. Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 2012;154:682-686. e682.
4. Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 2011;31:1877-1884.
5. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146:508-512.
6. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular agerelated macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-671.
7. Shah AR, Del Priore LV. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. Br J Ophthalmol 2009;93: 1027-1032.
8. Muether PS, Hermann MM, Viebahn U, et al. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Ophthalmology 2012;119:2082-2086.
9. Muether PS, Droege KM, Fauser S. Vascular endothelial growth factor suppression times in patients with diabetic macular oedema treated with ranibizumab. Br J Ophthalmol 2014; 98:179-181.
10. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114:2179-2182.
11. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007;27:1260-1266.
12. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-733.
13. Hoang QV, Jung JJ, Mrejen S, Freund KB. Influence of axial length and postinjection reflux on sustained intraocular pressure elevation as a result of intravitreal anti-vascular endothelial growth factor therapy. Retina 2014;34:519-524.
14. Weinberg DV, Shapiro H, Ehrlich JS. Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology 2013; 120:1278-1282.
15. Baek JS, Cho HJ, Cho SW, et al. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes. Retina 2013;33:467-473.
16. Ozkaya A, Alkin Z, Yazici AT, Demirok A. Comparison of intravitreal ranibizumab in phakic and pseudophakic neovascular age-related macular degeneration patients with good baseline visual acuity. Retina 2014;34:853-859.
17. Tan LE, Orilla W, Hughes PM, et al. Effects of vitreous liquefaction on the intravitreal distribution of sodium fluorescein, fluorescein dextran, and fluorescent microparticles. Invest Ophthalmol Vis Sci 2011;52:1111-1118.
18. Wu WC, Chen CC, Liu CH, et al. Plasmin treatment accelerates vascular endothelial growth factor clearance from rabbit eyes. Invest Ophthalmol Vis Sci 2011;52: 6162-6167.
19. Christoforidis JB, Williams MM, Wang J, et al. Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy. Retina 2013; 33:946-952.
20. Ahn J, Kim H, Woo SJ, et al. Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes. J Ocul Pharmacol Ther 2013;29:612-618.
21. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 2007;144:124-126.
22. Mehta S, Blinder KJ, Shah GK, et al. Intravitreal bevacizumab for the treatment of refractory diabetic macular edema. Ophthalmic Surg Lasers Imaging 2010;41:323-329.
23. Smailhodzic D, Muether PS, Chen J, et al. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology 2012;119:2304-2311.
24. Hagstrom SA, Ying GS, Pauer GJ, et al. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 2013;120:593-599.